Caribou Biosciences Flags Funding Needs, Forecasts Q4 Loss and $734M CB-011 Sales
Caribou Biosciences forecasts a Q4 2025 loss of $0.33 per share on $2.53 million revenue, improving EPS by 15.4% and revenue by 21.4% year-over-year. At a Citi Summit, the company outlined its pivotal-ready Vispa-cel trial plan, flagged financing needs and noted CB-011 therapy projection of $734 million in 2040 sales.
1. Q4 2025 Guidance
Caribou Biosciences is expected to report a Q4 2025 loss of $0.33 per share on revenues of $2.53 million, marking year-over-year EPS improvement of 15.4% and revenue growth of 21.4%. This guidance will serve as a key indicator of the company’s path toward profitability in its genome editing platform business.
2. Vispa-cel Plan and Funding Needs
At the Citi Summit, Caribou outlined its pivotal-ready study design for the Vispa-cel allogeneic T-cell therapy targeting hematologic cancers. Management signaled that additional financing will be required to support trial initiation, dose escalation and manufacturing scale-up.
3. CB-011 Sales Outlook
Analysts estimate that Caribou’s CB-011 cell therapy could achieve $734 million in annual sales by 2040, reflecting strong long-term market potential for its CAR-T pipeline. This projection highlights CB-011 as a major growth driver and value catalyst within the company’s portfolio.
4. Investor Conferences
The company plans to present at upcoming investor conferences to update stakeholders on clinical milestones, financial strategy and capital planning. These presentations will allow management to address questions on trial timelines, funding requirements and commercialization outlook.